It was in the 1960s that CBD, THC, and Cannabigerol or CBG, a minor cannabinoid, were discovered. CBG is a cannabinoid that is rare and found in small quantities, less than 1%, in hemp and other mature medical cannabis plants. It is a compound that is considered non-psychoactive. It is just like CBD, the other cannabinoid, in the fact that it produces no euphoric effects. There has been an increase in the funding of research into cannabinoids, and this has led to studies on CBG which is showing that this compound has many medical benefits. It is only now that the full potential of CBG is being understood.
This is the year that CBG was discovered to be present in the varieties of cannabis that was present in flowers that were immature or just budding. In this same year, it was also discovered that humans had an endocannabinoid system that did interact with plant cannabinoids.
The acidic version of CBG, known as CBGA, was isolated from the cannabis plant. Research showed that this acid was the biological originating point for all cannabinoids, like THC, THCV, CBC, CBD, and CBN. This acidic type of CBG has been called the “The Mother of All Cannabinoids.”
This was the year when the first acknowledged research was conducted in the effects of CBG. This research concentrated on how CBG affected those people who suffered from glaucoma. It established the fact that there was a reduction in intraocular pressure when CBG was used. There was also an increase in aqueous flow that was as high as two or threefold compared to those who has not undergone CBG treatment.
CBG showed promising results on glaucoma, but in spite of this, no study was conducted on CBG for the next 17 years after 1990. It was only in 2007, that two universities in the United Kingdom took up studies on CBG, separately. One of these concentrated on studying the help in bone growth afforded by CBG. The other university studied the potential that CBG had for treating psoriasis. It studied the action that CBG had on skin. In this study, it was established that human skin had some CB2 receptors and that the use of CBG inhibited the proliferation of keratinocyte, thus allowing it to be considered as a treatment for psoriasis.
The studies in 2007 kindled an interest in the presence of CB2 receptors in the skin, and the benefits of CBG for psoriasis, leading to further research being conducted on using CBG as a powerful anti-fungal that can treat the bacterium MRSA or Methicillin-resistant Staphylococcus aureus. MRSA has always shown a great resistance to most antibiotics. However, this bacterium was not immune to CBG.
Italian and Israeli research centers published a review article in this year that pointed to the beneficial impact that CBG had when used on cancer patients, by its ability to reduce the size of tumors that then helped them to live longer lives. This review established that CBG worked as antiproliferative and did this better than other cannabinoids used to reduce the size of tumors causing cancer.
Researchers in Spain focused on the use of CBG to treat Huntington’s disease. This research was mainly through animal trials, but the researchers concluded that CBG could be of use in treating neurological disorders and acted as powerful neuroprotection. At this time, other studies also concluded that CBG could be effective in treating an overactive bladder.
This study has just recently been concluded. It studied the effect CBG had on anxiety and depression. As this compound is non-psychoactive, when it is given to those patients who were depressed or anxious, they would not feel the paranoia that can come from treatment with large amounts of THC. Researchers concluded that the use of CBG for treating anxiety and depression worked as well as THC and had no psychoactive effects. CBG directly affected CB2 receptors in the endocannabinoid system in the body, instead of only the CB1 receptors that THC targeted.
You can get a small amount of CBG in many Hemgenix products already. Here, we go in for whole plant extraction, which allows a full spectrum of Active CBD products and preserves the entourage effect of a large range of cannabinoids. Combining cannabinoids gives a range of health benefits with great potential and is known as the Entourage Effect. Later this week, Hemegenix will release a cannabinoid specific product. This will be an isolated version of CBG. This form of isolated CBG will be the same as 99% Pure CBD Isolate and has the potential to be used in edible, topicals, and in vaping.